Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review (Q37218685)

19 August 2017

0 references

1 reference

title

Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review (English)

1 reference

19 August 2017

1 reference

1 reference

1 reference

1 reference

R Shabsigh

1

1 reference

19 August 2017

E D Crawford

series ordinal

2

1 reference

19 August 2017

A Nehra

series ordinal

3

1 reference

19 August 2017

K M Slawin

series ordinal

4

1 reference

19 August 2017

language of work or name

1 reference

11 September 2008

1 reference

International Journal of Impotence Research

19 August 2017

1 reference

19 August 2017

21

1 reference

19 August 2017

9-23

1 reference

19 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/ijir.2008.31

19 August 2017

0 references

cites work

Testosterone treatment comes of age: new options for hypogonadal men

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Risks of testosterone replacement therapy in ageing men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Prevalence of hypogonadism in males aged at least 45 years: the HIM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Male hypogonadism. Part I: Epidemiology of hypogonadism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Testosterone replacement therapy for late-onset hypogonadism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Male hypogonadism. Part II: etiology, pathophysiology, and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Risks of testosterone-replacement therapy and recommendations for monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Testosterone replacement therapy and the risk of prostate cancer. Is there a link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Testosterone supplementation therapy for older men: potential benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

A rational approach to androgen therapy for hypogonadal men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Testosterone and ageing: what have we learned since the Institute of Medicine report and what lies ahead?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Testosterone therapy for men at risk for or with history of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Effect of testosterone treatment on bone mineral density in men over 65 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Prostate cancer in men using testosterone supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Prostate cancer following testosterone replacement in Klinefelter syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Prostate cancer in Klinefelter syndrome during hormonal replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Prostate cancer after exogenous testosterone replacement therapy in a patient with pituitary insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Prostatic complications of testosterone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Intermittent androgen replacement for intense hypogonadism symptoms in castrated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Testosterone replacement therapy after primary treatment for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Herbal/hormonal dietary supplement possibly associated with prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

TESTOSTERONE UNDECANOATE: A NEW ORALLY ACTIVE ANDROGEN

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

7 January 2021

Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

7 January 2021

A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

7 January 2021

Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

7 January 2021

Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

7 January 2021

Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

7 January 2021

Prostate cancer after exogenous testosterone treatment for impotence

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

7 January 2021

Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

7 January 2021

Clinical significance of high-grade prostatic intraepithelial neoplasia in transurethral resection specimens

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

7 January 2021

Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.31

7 January 2021

Identifiers

DOI

10.1038/IJIR.2008.31

1 reference

19 August 2017

1 reference